Journey Medical (NASDAQ:DERM) Posts Earnings Results, Beats Expectations By $0.30 EPS

Journey Medical (NASDAQ:DERM) announced its quarterly earnings data on Wednesday. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.30, Zacks reports. The business had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%.

Journey Medical Stock Up 1.3 %

Shares of NASDAQ DERM traded up $0.07 during trading hours on Friday, hitting $5.99. The company had a trading volume of 13,652 shares, compared to its average volume of 86,195. Journey Medical has a 1-year low of $3.20 and a 1-year high of $6.89. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The firm’s 50 day moving average is $5.05 and its 200-day moving average is $5.16. The stock has a market capitalization of $125.21 million, a P/E ratio of -6.36 and a beta of 0.97.

Analyst Ratings Changes

Separately, Alliance Global Partners reissued a “buy” rating on shares of Journey Medical in a research report on Thursday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $9.67.

Insider Buying and Selling

In other news, CEO Claude Maraoui sold 14,905 shares of Journey Medical stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.01, for a total value of $74,674.05. Following the completion of the transaction, the chief executive officer now owns 2,052,418 shares of the company’s stock, valued at $10,282,614.18. This trade represents a 0.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders have sold 105,831 shares of company stock worth $536,622. Insiders own 13.16% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.